Prudential Financial Inc. purchased a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) during the second quarter, HoldingsChannel reports. The institutional investor purchased 5,913 shares of the biotechnology company’s stock, valued at approximately $1,045,000.
Several other hedge funds have also bought and sold shares of AXON. Cullen Frost Bankers Inc. acquired a new stake in shares of Axon Enterprise in the second quarter worth approximately $31,000. Credit Agricole S A acquired a new stake in shares of Axon Enterprise in the second quarter worth approximately $35,000. TCI Wealth Advisors Inc. acquired a new stake in shares of Axon Enterprise in the second quarter worth approximately $43,000. Financial Insights Inc. acquired a new stake in shares of Axon Enterprise in the second quarter worth approximately $44,000. Finally, Tobam purchased a new position in shares of Axon Enterprise in the 2nd quarter worth $47,000. Institutional investors and hedge funds own 75.45% of the company’s stock.
In other Axon Enterprise news, insider Jeffrey C. Kunins sold 3,169 shares of the firm’s stock in a transaction dated Friday, September 24th. The shares were sold at an average price of $175.61, for a total transaction of $556,508.09. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CRO Joshua Isner sold 11,083 shares of the firm’s stock in a transaction that occurred on Thursday, September 9th. The shares were sold at an average price of $183.37, for a total transaction of $2,032,289.71. Following the transaction, the executive now owns 332,491 shares in the company, valued at approximately $60,968,874.67. The disclosure for this sale can be found here. Insiders sold 594,445 shares of company stock worth $109,519,770 in the last 90 days. 2.30% of the stock is owned by company insiders.
Axon Enterprise stock opened at $179.86 on Thursday. The stock’s 50 day moving average price is $176.22 and its 200 day moving average price is $170.65. The firm has a market capitalization of $12.31 billion, a PE ratio of -449.64 and a beta of 0.40. Axon Enterprise, Inc. has a one year low of $115.57 and a one year high of $212.37.
Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Monday, November 15th. The biotechnology company reported $1.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.91. Axon Enterprise had a negative net margin of 2.37% and a negative return on equity of 2.26%. The firm had revenue of $231.99 million for the quarter, compared to the consensus estimate of $201.11 million. During the same period in the prior year, the firm posted ($0.01) EPS. The firm’s revenue was up 39.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Axon Enterprise, Inc. will post -0.85 earnings per share for the current year.
About Axon Enterprise
Axon Enterprise, Inc engages in the development, manufacturing, and sale of conducted electrical weapons for personal defense. It operates through the TASER Weapons and Software and Sensors segments. The TASER Weapons segment sells conducted electrical weapons, accessories, and other related products and services.
See Also: What is a Buy-Side Analyst?
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.